JO3375B1 - أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) - Google Patents

أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)

Info

Publication number
JO3375B1
JO3375B1 JOP/2011/0327A JOP20110327A JO3375B1 JO 3375 B1 JO3375 B1 JO 3375B1 JO P20110327 A JOP20110327 A JO P20110327A JO 3375 B1 JO3375 B1 JO 3375B1
Authority
JO
Jordan
Prior art keywords
human
tl1a
ligand
diseases
disorders
Prior art date
Application number
JOP/2011/0327A
Other languages
English (en)
Inventor
J Classon Brendan
Skokos Dimitris
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3375B1 publication Critical patent/JO3375B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بجسم مضاد بشري بالكامل أو شظية ربط لمولد ضد من جسم مضاد بشري، حيث ترتبط نوعياً وتثبط المركب الترابطي البشري 1A (hTL1A) المشابه لـ TNF. تكون الأجسام المضادة لـ hTL1A البشرية نافعة في علاج الأمراض والاضطرابات المتعلقة بـ TL1A، مثل الأمراض أو الاضطرابات الالتهابية، مثل أمراض التهاب الأمعاء، وتتضمن التهاب القولون التقرحي، ومرض كروهن، والتهاب المفاصل الروماتويدي، وما إلى ذلك؛ وأمراض أو اضطرابات المناعة الذاتية، مثل التصلب المتعدد، ومرض السكر، وما إلى ذلك؛ والتفاعلات التحساسية، مثل الربو والتهاب الرئة التحساسي.
JOP/2011/0327A 2010-11-08 2011-10-31 أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) JO3375B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41127610P 2010-11-08 2010-11-08
US201161478309P 2011-04-22 2011-04-22

Publications (1)

Publication Number Publication Date
JO3375B1 true JO3375B1 (ar) 2019-03-13

Family

ID=45002143

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0327A JO3375B1 (ar) 2010-11-08 2011-10-31 أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)

Country Status (22)

Country Link
US (3) US8642741B2 (ar)
EP (1) EP2638069B1 (ar)
JP (2) JP6076911B2 (ar)
KR (1) KR101896129B1 (ar)
CN (1) CN103261228B (ar)
AR (1) AR083785A1 (ar)
AU (1) AU2011326097B2 (ar)
BR (1) BR112013011245A2 (ar)
CA (1) CA2816799C (ar)
CL (1) CL2013001279A1 (ar)
EA (1) EA030397B1 (ar)
IL (1) IL226172A (ar)
JO (1) JO3375B1 (ar)
MX (1) MX355580B (ar)
MY (1) MY185006A (ar)
NZ (2) NZ610294A (ar)
PH (1) PH12013500912A1 (ar)
SG (2) SG190176A1 (ar)
TW (1) TWI606118B (ar)
UY (1) UY33715A (ar)
WO (1) WO2012064682A1 (ar)
ZA (1) ZA201304114B (ar)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
BR112014006390A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
AU2012315474B2 (en) * 2011-09-30 2017-10-26 Teva Pharmaceuticals Australia Pty Ltd. Antibodies against TL1a and uses thereof
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
BR112015010691A2 (pt) 2012-11-13 2017-08-22 Regeneron Pharma Anticorpo que se liga especificamente ao receptor de procineticina (prokr), seu uso no tratamento ou atenuação da dor e composição farmacêutica que o compreende
JP2016503818A (ja) * 2013-01-02 2016-02-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｌ１ａと結合する抗体およびその使用
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP4105236A1 (en) * 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
AU2014348676B2 (en) * 2013-11-13 2020-06-18 Bristol-Myers Squibb Company Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
US10160805B2 (en) 2014-07-11 2018-12-25 New York University Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
WO2016077720A1 (en) * 2014-11-14 2016-05-19 Protein One, Llc Binding agents and uses thereof
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US20180319889A1 (en) * 2015-11-02 2018-11-08 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN109462996A (zh) * 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
JP7012665B6 (ja) 2016-05-09 2023-12-14 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌ１ａ抗体およびその使用
CN110121509B (zh) 2016-10-26 2024-05-07 西达-赛奈医疗中心 中和抗tl1a单克隆抗体
WO2018237159A1 (en) 2017-06-21 2018-12-27 Cephalon, Inc. Cation exchange chromatography wash buffer
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
RU2689522C1 (ru) * 2018-09-11 2019-05-28 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующая слитый белок, состоящий из растворимого внеклеточного домена человеческого tnfr1 и константной части тяжёлой цепи человеческого igg4
CA3121162A1 (en) * 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
WO2020232125A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices
PH12022550978A1 (en) 2019-10-24 2023-10-09 Cedars Sinai Medical Center Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
EP4162067A4 (en) * 2020-06-03 2024-07-10 Cedars-Sinai Medical Center METHODS AND SYSTEMS FOR MEASURING THE RECURRENCE OF POSTOPERATIVE DISEASES
JP2024508762A (ja) * 2021-02-18 2024-02-28 プロメテウス バイオサイエンシーズ，インク． 抗ｔｌ１ａ抗体組成物及び肺における治療方法
MX2023009622A (es) * 2021-02-18 2023-08-28 Prometheus Biosciences Inc Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos.
CN116253796A (zh) * 2022-09-21 2023-06-13 三优生物医药(上海)有限公司 靶向冠状病毒的中和抗体、其抗原结合片段及其用途
WO2024239006A1 (en) 2023-05-17 2024-11-21 Genentech, Inc. Anti-tl1a antibody therapeutic methods
AU2024324300A1 (en) 2023-08-11 2026-02-12 Paragon Therapeutics, Inc. Tl1a binding antibodies and methods of use
WO2025076081A1 (en) 2023-10-03 2025-04-10 Absci Corporation Tl1a associated antibody compositions and methods of use
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
CN120530139A (zh) * 2023-12-29 2025-08-22 成都优洛生物科技有限公司 抗tl1a抗体或其抗原结合片段及应用
EP4592319A1 (en) * 2024-01-26 2025-07-30 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Antibodies capable of specifically binding tnf-like ligand 1a and use thereof
CN120424214A (zh) * 2024-02-05 2025-08-05 三生国健药业（上海）股份有限公司 一种抗tl1a抗体及其制备方法和用途
CN120818053A (zh) * 2024-04-11 2025-10-21 北京伟德杰生物科技有限公司 Tl1a抗体及其应用
CN120173113A (zh) * 2025-03-11 2025-06-20 江苏荃信生物医药股份有限公司 抗人tl1a单克隆抗体及其相关试剂盒和检测方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP1210435A1 (en) * 1999-08-04 2002-06-05 Amgen Inc. Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY
AU2002351208A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
ES2428321T3 (es) * 2003-08-20 2013-11-07 University Of Miami Composiciones y métodos para tratar la enfermedad del pulmón inflamado
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
WO2006127900A2 (en) * 2005-05-25 2006-11-30 Biogen Idec Ma Inc. Tl1a in the treatment of disease
AU2006284922B2 (en) * 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
WO2009013543A2 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to kdr and uses thereof - 035
UA104132C2 (en) * 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)

Also Published As

Publication number Publication date
EA030397B1 (ru) 2018-07-31
IL226172A (en) 2016-08-31
BR112013011245A2 (pt) 2020-08-04
US20120114654A1 (en) 2012-05-10
CA2816799A1 (en) 2012-05-18
US9556277B2 (en) 2017-01-31
JP2014500014A (ja) 2014-01-09
NZ610294A (en) 2015-06-26
KR101896129B1 (ko) 2018-09-07
MY185006A (en) 2021-04-30
CN103261228B (zh) 2016-02-10
ZA201304114B (en) 2014-02-26
TWI606118B (zh) 2017-11-21
UY33715A (es) 2012-05-31
SG190176A1 (en) 2013-06-28
TW201233796A (en) 2012-08-16
MX2013005141A (es) 2013-07-03
CA2816799C (en) 2021-02-16
KR20130132842A (ko) 2013-12-05
US8642741B2 (en) 2014-02-04
EA201370105A1 (ru) 2013-12-30
NZ706986A (en) 2016-04-29
EP2638069B1 (en) 2018-01-03
EP2638069A1 (en) 2013-09-18
US20170096491A1 (en) 2017-04-06
AU2011326097A1 (en) 2013-05-09
AR083785A1 (es) 2013-03-20
WO2012064682A1 (en) 2012-05-18
US20140120109A1 (en) 2014-05-01
JP2016220693A (ja) 2016-12-28
SG10201504265RA (en) 2015-06-29
IL226172A0 (en) 2013-07-31
JP6076911B2 (ja) 2017-02-08
AU2011326097B2 (en) 2015-08-20
CL2013001279A1 (es) 2014-03-07
CN103261228A (zh) 2013-08-21
MX355580B (es) 2018-04-06
JP6272970B2 (ja) 2018-01-31
PH12013500912A1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
JO3375B1 (ar) أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
NZ610592A (en) Anti-il-23 antibodies
JO3097B1 (ar) الأجسام المضادة c-Met
NZ602166A (en) Antibodies to il-6 and use thereof
NZ630363A (en) Anti-kit antibodies and uses thereof
WO2011139974A3 (en) Anti-pai-1 antibodies and methods of use thereof
MX2014006158A (es) Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
PE20080333A1 (es) Agentes para prevenir o tratar enfermedades inflamatorias
NZ610734A (en) Human antibodies to the glucagon receptor
MY157173A (en) Modified humanised anti-interleukin-18
PH12015501994B1 (en) Antibodies that bind il-23
UA105405C2 (ru) Гуманизированное антитело против человеческого il-22ra
GB2488091A (en) Humanized anti-interleukin 3 receptor alpha chain antibodies
MX2013013329A (es) Bloqueo de interacciones de factor de necrosis tumoral como ligando 1a - receptor de muerte 3 (tl1a-dr3) para mejorar la patologia mediada por las celulas t y los anticuerpos para los mismos.
CL2007003479A1 (es) Anticuerpo monoclonal humano anti-cd22 o un fragmento de union a antigeno del mismo; acido nucleico, vector, celula huesped; método de preparacion; composicion; inmunoconjugado; y su uso para inhibir el crecimiento de un tumor o tratar un desorden inflamatorio o autoinmune en un sujeto.
RU2013110844A (ru) АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
NZ612175A (en) Anti ccr4 antibodies and uses thereof
MY165499A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
FI3172232T3 (fi) TREM-1-vasta-aineiden kohdennettu mutageneesi viskositeetin alentamista varten
MY163133A (en) Humanized il-25 antibodies
WO2015095863A3 (en) Alpha-enolase specific antibodies and method of use in immune diseases
IN2012DN01981A (ar)
MX2018004039A (es) Anticuerpos humanos para ligando tipo factor de necrosis tumoral (tnf) humano 1a (tl1a).
MY176745A (en) Method of treating a tl1a-associated disease or disorder with human antibodies to tl1a